1. Home
  2. INO vs LFVN Comparison

INO vs LFVN Comparison

Compare INO & LFVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inovio Pharmaceuticals Inc.

INO

Inovio Pharmaceuticals Inc.

HOLD

Current Price

$1.10

Market Cap

90.5M

Sector

Health Care

ML Signal

HOLD

Logo Lifevantage Corporation (Delaware)

LFVN

Lifevantage Corporation (Delaware)

HOLD

Current Price

$6.24

Market Cap

78.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INO
LFVN
Founded
1979
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.5M
78.0M
IPO Year
1999
1996

Fundamental Metrics

Financial Performance
Metric
INO
LFVN
Price
$1.10
$6.24
Analyst Decision
Buy
Strong Buy
Analyst Count
4
1
Target Price
$6.75
$11.00
AVG Volume (30 Days)
1.5M
885.6K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
3.56%
EPS Growth
54.18
226.09
EPS
N/A
0.30
Revenue
$42,220,086.00
$203,204,000.00
Revenue This Year
$20,156.19
N/A
Revenue Next Year
$421.95
N/A
P/E Ratio
N/A
$20.67
Revenue Growth
19.37
1.86
52 Week Low
$1.03
$3.90
52 Week High
$2.86
$15.00

Technical Indicators

Market Signals
Indicator
INO
LFVN
Relative Strength Index (RSI) 43.35 43.63
Support Level $1.03 $5.67
Resistance Level $1.23 $7.15
Average True Range (ATR) 0.05 1.03
MACD 0.01 -0.26
Stochastic Oscillator 45.00 14.66

Price Performance

Historical Comparison
INO
LFVN

About INO Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

About LFVN Lifevantage Corporation (Delaware)

Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.

Share on Social Networks: